AGS Associates’ Post

📰 The market is really accelerating in the Neuroscience world now following the first wave of new Alzheimer's drugs in over a decade. 🏞 Swiss based Asceneuron SA specialises in the field of tauopathies, and has received $100mm dollars in series C funding to take their oral small molecule drug ASN51 into Phase II clinical studies. 🧠 Phase I studies showed ASN51 is taken up by the central nervous system and can impact the OGA enzyme.  Asceneuron is hoping that ASN51’s novel mode of action and convenient oral formulation will give it an advantage over these early market entrants such as Eli Lilly and Company, and Eisai US Biogen. 🛑 Inhibiting the OGA enzyme has also shown early promise in preventing the aggregation of proteins linked to other neurodegenerative diseases including Parkinson’s disease and amyotrophic lateral sclerosis. Asceneuron SA Spun out of Merck in 2012, and has developed another clinical stage OGA inhibitor in the form of ASN90, which is currently being targeted as a potential treatment for a tau-related disease called progressive supranuclear palsy. #neuroscience #seriescfunding #investment #pharma #alzheimers

🧠 Exciting News from 2023: Neuroscience Takes Center Stage in Biopharma Investments! Despite a downturn in overall biopharma investment, neuroscience experienced a remarkable surge in financial activity last year. As highlighted by J.P. Morgan's reports, late-stage mergers and acquisitions in the neuroscience sector soared, underscoring its growing importance in the industry. At Neuroservices-Alliance, we're thrilled to witness this trend firsthand, reflecting the promising innovations and regulatory support driving investments in CNS research. Stay tuned as we continue to lead the way in preclinical in vitro and in vivo electrophysiology studies, contributing to the advancement of neuroscience therapies. Read the below article from Biospace to learn more ⬇️ #Neuroscience #BiopharmaInvestments #CNSResearch #NeuroservicesAlliance 🧬🔬 https://lnkd.in/g5URrqgU

Over the past decade, only 53.1% of investigational drugs in #neurology transitioned from Phase III to New Drug Application or Biologics License Application – a lower rate compared to other disease areas. However, a setback in research does not indicate a lack of progress, but rather an opportunity to identify what works and what doesn’t. It is imperative for #lifescience and #neuroscience leaders to ensure that we learn from these setbacks and pivot towards newer approaches. With advancements in technology and research methodologies, we are closer to accelerating the development of therapies that have the potential to transform the lives of patients. Read the full Genetic Engineering & Biotechnology News article: https://lnkd.in/eJGvY3cg

Neuroscience Takes Centre Stage: AbbVie's Strategic Move in Parkinson’s Disease AbbVie's recent acquisition of Mitokinin, a neuroscience biotech company with a focus on Parkinson's disease (PD), underscores the growing significance of neuroscience in the pharmaceutical landscape. Valued at over $650 million, this deal amplifies the industry's recognition of the urgent need for innovative treatments targeting neurological disorders. The neuroscience sector has become a focal point for major pharmaceutical-biotech collaborations, with companies like Merck and Novartis making substantial investments in neurodegenerative disease-focused entities. Merck's acquisition of Caraway Therapeutics for up to $610 million and Novartis' deal with DTx Pharma for up to $1 billion highlight a trend of pharma giants seeking to bolster their portfolios in the realm of neuroscience. The prevalence of conditions like PD, affecting over 8.5 million individuals worldwide, amplifies the demand for groundbreaking treatments. AbbVie's strategic move to access Mitokinin's PINK1 activator, designed to address mitochondrial dysfunction—a contributing factor to PD—underscores the pharmaceutical industry's commitment to exploring novel avenues for neurological disorders. As the global burden of neurological diseases continues to rise, pharmaceutical companies are actively seeking partnerships and acquisitions to fill the void in treatment options. The challenges posed by conditions such as PD, Alzheimer's, and depression necessitate a collaborative approach, prompting industry leaders to invest significantly in promising biotech ventures. AbbVie's foray into Mitokinin's innovative approach serves as a testament to the pharmaceutical industry's collective effort to develop transformative solutions for unmet medical needs in neuroscience. The string of recent deals in this space reflects a shared commitment to advancing research and bringing novel therapies to the forefront, addressing the pressing health challenges posed by neurological disorders. In this landscape of evolving partnerships and acquisitions, the momentum in neuroscience research highlights not only the scientific advancements but also the strategic imperatives for pharma companies to stay at the forefront of innovation in tackling complex neurological conditions. #neuroscience #neurology #mentalhealth #pharma #biotech #deals #dealmaking #acquisitions #merck #neurentis https://lnkd.in/dD6rahRE

Exciting news in the world of neurology! 🧠💡 Neurosterix, a Swiss startup, just secured a whopping $63M in funding to develop breakthrough treatments for neurological disorders. 🚀 Check out the full story here: https://lnkd.in/e3mhSz2e #startupnews #Neurology #Innovation

𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧 𝐍𝐞𝐰𝐬: 𝐀𝐛𝐛𝐯𝐢𝐞 𝐭𝐨 𝐚𝐜𝐪𝐮𝐢𝐫𝐞 𝐂𝐞𝐫𝐞𝐯𝐞𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 Some exciting news on the pharmaceutical acquisition front as AbbVie have forked out an eyewatering $8.7 billion for Cerevel Therapeutics. This will give Abbvie access to the broad pipeline of clinical stage products in Cerevel's pipeline, across Parkinson's, mood disorders and schizophrenia. Adding this to Abbvie's already expansive neuro pipeline, they have the potential to become market leaders with a diverse portfolio across Alzheimer's, Parkinson's, mood disorders, anxiety, ALS and various other areas. Hopefully this influx of investment and Abbvies economies of scale will enable Cerevel to push their late stage products over the line! Follow Warman O'Brien for all the latest updates in the life sciences industry! #acquisition #goodnews #neurology #cns

We have looked under the lamppost for long enough. Now, we just have to accept that the car keys are somewhere else. Over 10 years, only 53.1% of investigational drugs in neurology transitioned from Phase III to New Drug Application—lower than almost any other area. It’s time to move away from measuring a large number of things to measuring a large number of times. We need to measure the CNS at a frequency that is aligned with how it functions. Read my article on Genetic Engineering & Biotechnology News ➡️https://lnkd.in/gxPWyps9

✨ 𝗧𝗮𝗸𝗲𝗱𝗮 𝗦𝗲𝗰𝘂𝗿𝗲𝘀 $𝟭.𝟮 𝗕𝗶𝗹𝗹𝗶𝗼𝗻 𝗗𝗲𝗮𝗹 𝘄𝗶𝘁𝗵 𝗗𝗲𝗴𝗿𝗼𝗻 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀 𝗳𝗼𝗿 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆, 𝗡𝗲𝘂𝗿𝗼𝘀𝗰𝗶𝗲𝗻𝗰𝗲, 𝗮𝗻𝗱 𝗜𝗻𝗳𝗹𝗮𝗺𝗺𝗮𝘁𝗶𝗼𝗻 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗜𝗻 𝗠𝗮𝘆 𝟮𝟬𝟮𝟰, Takeda has ventured to #Shanghai to finalize a $1.2 billion biobucks agreement aimed at developing new candidates in #oncology, #neuroscience, and #inflammation. The Japanese pharmaceutical giant has partnered with Degron Therapeutics, a molecular glue biotech company, in a deal that includes an undisclosed upfront payment, equity investment 💰, and #milestone payments. Additionally, Degron will be eligible for royalties and a share of future sales. The collaboration will focus on creating molecular glue degraders targeting multiple disease areas. Utilizing Degron’s GlueXplorer platform, the companies will identify new therapeutic targets selected by Takeda. Degron will spearhead the initial research phase before handing over the reins to Takeda for further development. 𝗕𝗿𝗼𝘄𝘀𝗲 𝗮𝘁 𝗼𝘂𝗿 𝗟𝗶𝗻𝗸𝗲𝗱 𝗥𝗲𝗽𝗼𝗿𝘁 👉: https://bit.ly/4dS1M0k #Neurology #CancerResearch #Molecularglue   #Biotechnology #prophecymarketinsights

2023 was a horrible year for #initialpublicofferings in #biotech. However, the #IPO market continues to grow in early 2024 with two companies jumping into the fray—Alto Neuroscience and Kyverna Therapeutics. https://lnkd.in/g8BRY6ef #biotechnology #IPOnews #neuroscience #CARTcells BioSpace

As the new year approaches, we wanted to draw attention to some positive movement in the neurologic investment space. Just this month, Bristol Myers Squibb acquired Karuna Therapeutics for $14bn, Merck acquired Caraway Therapeutics, Inc. for $610mm, and AbbVie acquired Cerevel Therapeutics for $8.7bn. When big names like these commit $20 bn to strengthen their neuroscience portfolios, we appear to be at high amplitude neuroscience investment moment such as described by Dr. Harry Tracy in his article, “The Neuro Funding Roller Coaster”. With another positive cycle underway, it is hard not to feel optimistic about the future of Neuro-Innovators, LLC and neuroscience investments on the whole. As always, we would love to chat, come see us during J.P. Morgan Week in San Francisco. You can find Mark Cochran or Howison Schroeder at the 7th Annual Neuroscience Innovation Forum on Jan. 7, as well as at BIO Partnering and/ or the Bullpen from Jan. 8 through 11. Drop a comment or send us a message if you want to learn more about our path to improve the lives of millions of patients suffering from chronic stroke disabilities. We have a lot of exciting movement happening heading into J.P. Morgan Week! #sachs_nif #jpm2024 #jpm24 #biotechnologyinternational #bullpen #neurology #neuroscience #neuroplasticity #neuroinnovators #niv #merck #merckgroup #merckproud #bristolmyerssquibb #abbvie #abbvielife